Common variant of BCAS3 is associated with gout risk in Japanese population: the first replication study after gout GWAS in Han Chinese

Masayuki Sakiyama1,2†, Hirotaka Matsuo1,*†, Hirofumi Nakaoka3, Yusuke Kawamura1, Makoto Kawaguchi1, Toshihide Higashino1, Akiyoshi Nakayama1, Airi Akashi1, Jun Ueyama4, Takaaki Kondo4, Kenji Wakai5, Yutaka Sakurai6, Ken Yamamoto7, Hiroshi Ooyama8 and Nariyoshi Shinomiya1

Abstract

Background: Gout is a common disease resulting from hyperuricemia which causes acute arthritis. A recent genome-wide association study (GWAS) of gout identified three new loci for gout in Han Chinese: regulatory factor X3 (RFX3), potassium voltage-gated channel subfamily Q member 1 (KCNQ1), and breast carcinoma amplified sequence 3 (BCAS3). The lack of any replication studies of these three loci using other population groups prompted us to perform a replication study with Japanese clinically defined gout cases and controls.

Methods: We genotyped the variants of RFX3 (rs12236871), KCNQ1 (rs179785) and BCAS3 (rs11653176) in 723 Japanese clinically defined gout cases and 913 controls by TaqMan method. rs179785 of KCNQ1 is also evaluated by direct sequencing because of difficulties of its genotyping by TaqMan method.

Results: Although the variants of RFX3 and BCAS3 were clearly genotyped by TaqMan method, rs179785 of KCNQ1 was not, because rs179785 (A/G) of KCNQ1 is located at the last nucleotide (“A”) of the 12-bp deletion variant (rs200562977) of KCNQ1. Therefore, rs179785 and rs200562977 of KCNQ1 were genotyped by direct sequencing in all samples. Moreover, by direct sequencing with the same primers, we were able to evaluate the genotypes of rs179784 of KCNQ1 which shows strong linkage disequilibrium with rs179785 (D’ = 1.0 and r² = 0.99). rs11653176, a common variant of BCAS3, showed a significant association with gout (P = 1.66 x 10⁻³; odds ratio [OR] = 0.80); the direction of effect was the same as that seen in the previous Han Chinese GWAS. Two variants of KCNQ1 (rs179785 and rs179784) had a nominally significant association (P = 0.043 and 0.044; OR = 0.85 and 0.86, respectively), but did not pass the significance threshold for multiple hypothesis testing using the Bonferroni correction. On the other hand, rs200562977 of KCNQ1 and rs12236871 of RFX3 did not show any significant association with gout.

Conclusion: BCAS3 is a coactivator of estrogen receptor alpha, and the influence of estrogen to serum uric acid level is well known. Our present replication study, as did the previous gout GWAS, demonstrated the common variant of BCAS3 to be associated with gout susceptibility.

Keywords: Breast carcinoma amplified sequence 3 (BCAS3), Potassium voltage-gated Channel subfamily Q member 1 (KCNQ1), Regulatory factor X3 (RFX3), Single nucleotide polymorphisms (SNP), Urate, Uric acid
Background

Gout, which can also cause acute arthritis, is a common disease resulting from hyperuricemia. An increasing number of patients nowadays suffer from gout. Although various investigations aiming to elucidate the pathogenesis of this common disease are being conducted worldwide, most of the common genetic causes of gout remain to be clarified. Previous function-based genetic studies and genome-wide association studies (GWASs) have revealed that gout is associated with several genes, such as ATP-binding cassette transporter, subfamily G, member 2 (ABCG2/BCRP) and glucose transporter 9 (GLUT9/SLC2A9). Especially, by performing a GWAS of clinically-ascertained gout, our Japanese report identified five gout loci including MYL2-CUX2 and cornichon family AMPA receptor auxiliary protein 2 (CNIH-2) [6]. Subsequent fine mapping analysis of the MYL2-CUX2 region found that rs671 of aldehyde dehydrogenase 2 (ALDH2) is a gout locus which is an Asian specific one [7]. Li et al. recently performed a GWAS of clinically-ascertained gout and identified the following three new loci for gout in Han Chinese: regulatory factor X3 (RFX3), potassium voltage-gated channel subfamily Q member 1 (KCNQ1) and breast carcinoma amplified sequence 3 (BCAS3) [8]. However, there is no replication study of these three loci using other population groups. We therefore performed a replication study using Japanese clinically-defined gout cases and controls.

Methods

Patients and controls

This study was approved by the institutions' Ethical Committees (National Defense Medical College and Nagoya University). All procedures were performed in accordance with the Declaration of Helsinki, with written informed consent obtained from each subject. The cases comprised 723 gout patients assigned from Japanese male outpatients at Ryougoku East Gate Clinic (Tokyo, Japan). All patients were clinically diagnosed with primary gout according to the criteria established by the American College of Rheumatology [9]. Patients with inherited metabolic disorders, including Lesch–Nyhan syndrome and phosphoribosylpyrophosphate synthetase I superactivity, were excluded. Hyperuricemia was defined as the serum uric acid (SUA) level that exceeds 7.0 mg/dl (= 416.36 mol/l) according to the guideline of the Japanese Society of Gout and Nucleic Acid Metabolism [10]. The control group comprised 913 Japanese males without hyperuricemia and gout history, recruited from the participants in the Daiko Study, part of the Japan Multi-Institutional Collaborative Cohort Study (J-MICC Study) [11]. The mean age (± SD) of case and control groups was 45.5 years (± 10.6) and 53.5 years (± 10.3), respectively, and their mean body mass index was 25.3 kg/m² (± 3.6) and 22.9 kg/m² (± 2.9), respectively.

Genotyping

Genomic DNA was extracted from whole peripheral blood cells [12]. Genotyping of the three single nucleotide polymorphisms (SNPs), rs12236871 of RFX3, rs179785 of KCNQ1 and rs11653176 of BCAS3, was performed using the TaqMan method. However, direct sequencing was employed to confirm the genotypes in several samples of all of four groups, and rs179785 of KCNQ1 is located at the last nucleotide of this deletion variant (also see Figs. 2 and 3). Therefore, because it is difficult to genotype rs179785 using the TaqMan method, we performed the subsequent genotyping of rs179785 and rs200562977 by direct sequencing.
performed using the TaqMan method (Thermo Fisher Scientific, Waltham, MA, USA) employing a LightCycler 480 (Roche Diagnostics, Mannheim, Germany) [12] with minor modifications. For genotyping KCNQ1 variants, DNA sequencing analysis was performed with following primers: forward 5’-ACTTCCTGCTCTGCTTTC-3’ and reverse 5’-TGAAGGAAGTGACCCCTG-3’. Direct sequencing was performed using a 3130xl Genetic Analyzer (Thermo Fisher Scientific) [12].

Data analysis
The software R version 3.1.1 (http://www.r-project.org/) [13] with the GenABEL package was used for all calculations in the statistical analysis. The association analyses were examined using the chi-square test. The pairwise linkage disequilibrium (LD) was calculated using data from the 1000 Genomes phase 3 JPT (Japanese in Tokyo) [14]. All P values were two-tailed and P values of < 0.05 were regarded as statistically significant.

Results
A representative plots of genotyping results by TaqMan method is shown in Fig. 1. Although allelic discrimination plots of rs12236871 of RFX3 (Fig. 1a) and rs11653176 of BCAS3 (Fig. 1b) are clearly divided into three groups for each genotype (major allele homozygote, heterozygote and minor allele homozygote), the plots of rs179785 of KCNQ1 are clustered into four groups, labeled as Groups 1, 2, 3 and 4 in Fig. 1c. Thus, to confirm the genotypes of samples of Groups 1 and 2, direct sequencing was performed to analyze the DNA sequence around rs179785 of KCNQ1. Although the genotypes of almost all the samples in Group 2 shown in Fig. 1c were heterozygous (A/G) for rs179785 (Fig. 2a), the heterozygous 12-bp deletion variant of KCNQ1, rs200562977 (Fig. 2b), was frequently found in Group 1 samples in Fig. 1c. Actually, rs179785 (A/G) is located at the last nucleotide (“A”) of this 12-bp deletion variant (rs200562977), as shown in Fig. 3. Further direct sequencing analysis revealed that Groups 3 and 4 also include a
heterozygous 12-bp deletion variant, and several samples in Groups 2 and 4 exhibit a homozygous 12-bp deletion variant (Fig. 2c). These findings suggest that it is difficult to correctly genotype rs179785 of KCNQ1 using the TaqMan or DNA micro-array method. Therefore, in subsequent analyses, rs179785 and rs200562977 of KCNQ1 were genotyped by direct sequencing, not by the TaqMan method, in all samples. Moreover, by direct sequencing with the same primers, we were able to evaluate the genotypes of rs179784 of KCNQ1, which is located downstream from rs179785 by 305 bp (Fig. 3), and which shows strong linkage disequilibrium with rs179785 (D’ = 1.0 and r² = 0.99). For direct sequencing of the three variants of KCNQ1, the primers were designed as follows: 5′-ACTTCTCGCCTCTGCTTTC-3′ (forward primer) and 5′-TGAGGAAGTACCCCTG-3′ (reverse primer), respectively.

**Table 1** Association analysis of three loci with 723 clinically-defined gout cases and 913 controls

| Variant  | Gene   | Chr. Position | A1/A2 | Genotypes | Alleles frequency model |
|----------|--------|---------------|-------|-----------|-------------------------|
|          |        |               |       | A1/ A2    | A1/ A2                  |
|          |        |               |       | A1/ A2    | A2/ A2                  |
|          |        |               |       | A1/ A2    | A2/ A2                  |
| rs12336871 | RFC3   | 9             |      | 166/54   | 6/72                    |
| rs179785  | KCNQ1  | 11            |      | 196/277  | 102/102                 |
| rs200562977 | KCNQ1 | 11            |      | 575/142  | 6/72                    |
| rs179784  | BCAS3  | 11            |      | 288/331  | 104/104                 |
| rs11653176 | BCAS3 | 17            |      | 227/346  | 14/104                  |

**Discussion**

In this study, we were able, for the first time, to replicate the association between rs11653176 of BCAS3 and gout. rs2079742, another intronic SNP of BCAS3, was previously reported to have an association with SUA level at the genome-wide significance level; however, it was not replicated in the same report [5]. BCAS3 is a coactivator of estrogen receptor alpha (ER-α) and is overexpressed in breast cancer cells [15], in which it is associated with tumor grade and proliferation [16]. The influence of sex hormones on SUA level is well known [17]. Especially, estradiol is thought to affect SUA levels through mechanisms modulating renal urate reabsorption and...
secretion. Increased SUA levels in postmenopausal women could be caused by the loss of estradiol. In addition, SUA levels decrease in postmenopausal patients using postmenopausal hormone compared with patients not using it [18]. Our findings suggest that risk allele (C) of rs11653176 of BCAS3 may increase renal urate re-absorption which results in increase of SUA levels and gout risk. Thus, although additional genetic and/or functional analyses will be necessary, the common variant of BCAS3 might affect gout susceptibility in ways that are attributable to individual differences in responses to the effects of estrogen. Very recently, we have reported further GWAS of clinically-ascertained gout and identified 10 gout loci including HIST1H2BF-HISTI1H4E, solute carrier family 17 member 1 (SLC17A1), solute carrier family 22 member 12 (SLC22A12), NIPA like domain containing 1 (NIPAL1) and family with sequence similarity 35 member A (FAM35A) [19]. Together with these gout loci, BCAS3, which is originally identified by the Chinese gout GWAS, will be very important for personalized genome medicine and/or prevention of gout.

Conclusions

In summary, our present replication study demonstrated, as did a previous gout GWAS [8], an association between gout and the common variant of BCAS3. These findings suggest that the BCAS3 locus is likely to have a common pathophysiological risk for gout.

Abbreviations

ABC2G2/BCRP: ATP-binding cassette transporter subfamily G member 2/breast cancer resistance protein; BCAS3: Breast carcinoma amplified sequence 3; ER-α: Estrogen receptor alpha; GLUT9/SLC2A9: Glucose transporter 9/solute carrier family 2 member 9; GWAS: Genome-wide association study; J-MICC Study: Japan Multi-Institutional Collaborative Cohort study; JPT: Japanese in Tokyo; KCNQ1: Potassium voltage-gated channel subfamily Q member 1; LD: Linkage disequilibrium; OR: Odds ratio; RFX3: Regulatory factor X3; SNP: Single nucleotide polymorphisms; SUA: Serum uric acid

Acknowledgements

We would like to thank all the participants for their generous involvement in this study. We are especially indebted to K. Gotanda, Y. Morimoto, M. Miyazawa, S. Shimizu and T. Chiba for genetic analysis. We also thank H. Nakashima, T. Nakamura and K. Ichida for helpful discussions.

Funding

This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, including MEXT KAKENHI (Nos. 25293145, 17 K19863, 17 K19864 and 17H04128), the Ministry of Health, Labour and Welfare of Japan, the Ministry of Defense of Japan, the Kawano Masanori Memorial Foundation for Promotion of Pediatrics, and the Gout Research Foundation of Japan. The study was also supported by a JSPS KAKENHI Grant (No. 16H06277) and Grants-in-Aid for Scientific Research on Priority Areas (No. 17015018) and Innovative Areas (Nos. 22150001, 22150002) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology.

Availability of data and materials

All data and materials supporting the conclusions of this article are included within the article.

Authors’ contributions

MS, HM and HN conceived and designed this study. JU, TK, KW and HO collected samples and analyzed clinical data. MS, HM, MK, TH, AN, YK and AA performed genetic analysis. MS and HM performed statistical analyses. YS, KY and NS provided intellectual input and assisted with the preparation of the manuscript. MS and HM wrote the manuscript. MS and HM contributed equally to this work. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

This study was approved by the institutional Ethical Committee (National Defense Medical College and Nagoya University). All procedures were performed in accordance with the Declaration of Helsinki, with written informed consent obtained from each subject.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan. 2Department of Dermatology, National Defense Medical College, Tokorozawa, Japan. 3Division of Human Genetics, Department of Integrated Genetics, National Institute of Genetics, Mishima, Japan. 4Program in Radiological and Medical Laboratory Sciences, Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan. 5Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan. 6Department of Preventive Medicine and Public Health, National Defense Medical College, Tokorozawa, Japan. 7Department of Medical Chemistry, Kurume University School of Medicine, Kurume, Japan. 8Ryougoku East Gate Clinic, Tokyo, Japan.

Received: 28 December 2016 Accepted: 19 April 2018

Published online: 07 June 2018

References

1. Matsuo H, Takada T, Ichida K, Nakayama A, Ikebuchi Y, Ito K, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med. 2009;1:5ra11.
2. Woodward OM, Köttgen A, Coreh J, Boerwinkle E, Guggino WB, Köttgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009;106:10338–42.
3. Matsuo H, Ichida K, Takada T, Nakayama A, Nakashima H, Nakamura T, et al. Common dysfunctional variants in ABCG2 are a major cause of early-onset gout. Sci Rep. 2014;4:2013.
4. Sulem P, Guðbjartsson DF, Walters GB, Helgadóttir HT, Helgason A, Gundjohnson SA, et al. Identification of low-frequency variants associated with gout and serum uric acid levels. Nat Genet. 2011;43:1127–30.
5. Köttgen A, Albrecht E, Teumer A, Vitart V, Krumsieck J, Hundtemark C, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013;45:145–54.
6. Matsuo H, Yamamoto K, Nakaoa H, Nakayama A, Sakya M, Chiba T, et al. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Arn Rheum Dis. 2016;75:652–9. (epub ahead of print, on Feb 2, 2015)
7. Sakya M, Matsuo H, Nakaoa H, Yamamoto K, Nakayama A, Nakamura T, et al. Identification of rs671, a common variant of ALDH2, as a gout susceptibility locus. Sci Rep. 2016;6:25360.
8. Li C, Li Z, Liu S, Wang C, Han L, Cui L, et al. Genome-wide association analysis identifies three new risk loci for gout arthritis in Han Chinese. Nat Commun. 2015;6:7041.
9. Wallace SL, Robinson H, Masl AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheim. 1977;20:895–900.
10. The guideline revision committee of Japanese Society of Gout and Nucleic Acid Metabolism in Guideline for the Management of Hyperuricemia and
Gout. 2nd ed. Guideline for the Management of Hyperuricemia and Gout. Osaka: Medical Review; 2010.

11. Hamajima N, J-MICC Study Group. The Japan multi-institutional collaborative cohort study (J-MICC study) to detect gene-environment interactions for cancer. Asian Pac J Cancer Prev. 2007;8:317–23.

12. Sakiyama M, Matsuo H, Shimizu S, Chiba T, Nakayama A, Takada Y, et al. Common variant of leucine-rich repeat-containing 16A (LRRC16A) gene is associated with gout susceptibility. Hum Cell. 2014;27:1–4.

13. R Development Core Team. R Foundation for Statistical Computing. Vienna 2014.

14. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061–73.

15. Barlund M, Monni O, Weaver JD, Kauranenmi P, Sauter G, Heiskanen M, et al. Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. Genes Chromosomes Cancer. 2002;35:311–7.

16. Gururaj AE, Singh RR, Rayala SK, Holm C, den Hollander P, Zhang H, et al. MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proc Natl Acad Sci U S A. 2006;103:6670–5.

17. Adamopoulos D, Viassopoulos C, Seitanides B, Contoyiannis P, Vassilopoulos P. The relationship of sex steroids to uric acid levels in plasma and urine. Acta Endocrinol. 1977;85:198–208.

18. Hak AE, Choi HK. Menopause, postmenopausal hormone use and serum uric acid levels in US women—the third National Health and Nutrition Examination Survey. Arthritis Res Ther. 2008;10:R116.

19. Nakayama A, Nakaoka H, Yamamoto K, Sakiyama M, Shaukat A, Toyoda Y, et al. GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. Ann Rheum Dis. 2017;76(5):869–77.